Gujarat Themis Biosyn Ltd Q2 FY26 – 990 KL Fermentation, 102x P/E, and a Fresh Batch of Profit!
1. At a Glance
What happens when a biotech company with a ₹4,931 crore market cap, 102x P/E, and just ₹155 crore in sales decides to double its fermentation capacity? You get Gujarat Themis Biosyn Ltd (GTBL) — India’s OG fermentation chemist and proud parent of Rifamycin molecules. As of Q2 FY26 (Sep 2025), the company reported quarterly revenue of ₹42 crore, profit of ₹14.3 crore, and a net margin close to 33.7%, maintaining its usual “fermented money” efficiency.
After scaling up fermentation capacity from 450 KL to 990 KL and commencing commercial production on October 18, 2025, GTBL has finally turned its petri dishes into profit labs. The stock, trading at ₹453 per share, is up 24% in 3 months and nearly 40% over 6 months. Return ratios continue to impress: ROE at 21.7% and ROCE at 27.3%, while debt remains light at ₹71.5 crore (Debt/Equity = 0.27).
But there’s a catch — the company has only two major customers contributing 100% of its sales. So yes, the risk concentration here is tighter than an audit schedule before AGM.
2. Introduction
If “quiet compounders” had a spokesperson, Gujarat Themis Biosyn Ltd would be that nerdy kid in the backbench who keeps topping every year without saying a word. Founded in 1981 and now managed by Themis Medicare (themselves JV partners with Gedeon Richter of Hungary), GTBL specializes in fermentation-based Active Pharmaceutical Ingredients (APIs).
Their claim to fame? Being the first Indian company to commercially produce Rifampicin, the life-saving antibiotic for tuberculosis. Today, it produces Rifamycin-S and Rifamycin-O — intermediates for Rifampicin and Rifaximin, two of the most prescribed anti-infective drugs worldwide.
Yet, despite being small in sales terms (₹155 crore FY25), the company commands a market cap that’s nearly 32x its revenue. Why? Because it does one thing — and does it really, really well. Imagine a chef who only cooks one dish but does it Michelin-style. That’s GTBL in pharma form.
While peers chase the API-of-the-month trend, GTBL sticks to its bacteria and bioreactors like a monk to meditation. The fermentation gods must be pleased — because this company’s operating margins hover around 45-50%, a rarity even for big pharma.
3. Business Model – WTF Do They Even Do?
GTBL’s business is as concentrated as the broth inside its fermentation tanks. The company manufactures pharmaceutical intermediates using fermentation — a process where microbes do the heavy lifting instead of chemical reactors.
Rifamycin-S: Intermediate for Rifampicin, the TB-fighter.
Rifamycin-O: Intermediate for Rifaximin, used in traveler’s diarrhea, IBS, and liver diseases.
These are then sold to big boys like Lupin and Optrix Laboratories, who formulate and market the final APIs or finished drugs.
Revenue concentration? Extreme. Lupin contributes ~44%, Optrix ~56%. Luckily, both operate under “take-or-pay” contracts — which means even if they don’t buy, they still pay. The kind of contract every supplier dreams of and every auditor questions twice.
The company’s Vapi plant churns out up to 16,000 kg/month, and it’s expanding further with a ₹183 crore capex fully funded through internal accruals. Yes, zero borrowing for that — because GTBL makes cash faster than some startups make pitch decks.
Their new R&D block and CGMP pilot plant are coming up too, expected to be completed by FY26. Once done, GTBL aims to move up the value chain — think less “intermediate supplier,” more “API manufacturer.”
4. Financials Overview
Metric
Q2 FY26 (Sep 2025)
Q2 FY25
Q1 FY26
YoY %
QoQ %
Revenue (₹ Cr)
42.4
34.8
36.0
22.0%
17.8%
EBITDA (₹ Cr)
21.0
15.2
14.0
38.2%
50.0%
PAT (₹ Cr)
14.3
10.6
9.0
34.9%
58.9%
EPS (₹)
1.31
0.97
0.83
35.1%
57.8%
Annualized EPS = ₹1.31 × 4 = ₹5.24 At ₹453, that’s a P/E of 86x on annualized earnings — clearly priced for perfection and maybe divine fermentation.
Commentary: When your EBITDA margin is above 45% and you have no interest expense, you’re basically printing money. The quarter also coincides with their 990KL capacity announcement, so the next few quarters could be even juicier (pun intended).
5. Valuation Discussion – Fair Value Range
Let’s break it down like a nerdy auditor:
a) P/E Method: Industry average P/E = 32.4x GTBL’s FY25 EPS = ₹4.43 → Fair Value = ₹4.43 × 25–40 = ₹110–₹177 (theoretically). But market’s paying 102x, because fermentation stories sell better than valuation logic.
b) EV/EBITDA Method: EV = ₹4,993 Cr EBITDA (FY25) = ₹70 Cr EV/EBITDA = 71x (ouch). Sector average ≈ 18x → Fair Range = ₹70 × 18 = ₹1,260 Cr EV → Equity Value ≈ ₹1,200 Cr → ₹110–₹130/share
c) DCF (with zero hero assumption): If cash flow grows 15% for 5 years, terminal 4%, WACC 10% → Fair Value ≈ ₹150–₹180/share
🧾 Educational Disclaimer: This fair value range (₹110–₹180) is purely for learning purposes and not investment advice. The market doesn’t care about our Excel sheets — it cares about “fermentation expansion and export approvals.”
6. What’s Cooking – News, Triggers, Drama
Fermentation Capacity Explosion: On Oct 18, 2025, GTBL officially started commercial production at its expanded 990 KL facility in Vapi, Gujarat. That’s more
